Labetalol, a cross-over double blind controlled trial

Area of Science:

• Cardiology
• Pharmacology
• Clinical Hypertension Research

Background:

• Essential hypertension is a widespread condition requiring effective pharmacological management.
• Comparative studies are crucial for determining optimal treatment strategies for hypertension.
• Labetalol and methyldopa are established antihypertensive agents with distinct mechanisms of action.

Purpose of the Study:

• To compare the efficacy and tolerability of labetalol versus methyldopa in patients with essential hypertension.
• To assess the impact of these agents on blood pressure, heart rate, and adverse effects.

Main Methods:

• A double-blind, cross-over, dose-titrated study design was employed.
• Twenty patients with moderately severe essential hypertension participated.
• Blood pressure (lying and standing) and heart rate were monitored.

Main Results:

• Both labetalol and methyldopa significantly reduced systolic and diastolic arterial blood pressure to a comparable degree.
• Labetalol demonstrated a statistically significant reduction in heart rate, whereas methyldopa did not.
• Patient compliance exceeded 95% for both treatments, with a similar incidence of subjective adverse effects.

Conclusions:

• Labetalol and methyldopa are equally effective in reducing blood pressure in essential hypertension.
• Labetalol offers an additional benefit of heart rate reduction.
• Both drugs are well-tolerated and exhibit high compliance rates in this patient population.